Many stem cell therapies fail because transplanted cells do not survive. One of the most advanced examples of stem cell therapy is the use of adult…
See where grants have been awarded across Minnesota.
Melanie Graham, MPH, PhD and Quinn P. Peterson, PhD
Angela Panoskaltsis-Mortari, PhD, and Joseph Broomhead, MS
Human skeletal muscle is challenging to create because it is composed of many thin fibers that must be precisely aligned in complex patterns. To…
Jonathan Sachs, PhD
A major challenge in regenerative medicine is the ability to predict disease risk, therapeutic outcomes and personalize treatments. The goal of this…
Michael Barry, PhD
Alport Syndrome (AS) is a genetic disease caused by mutations in genes that form the structural foundations of the kidney, ear, and eye causing them…
Andres Crane, PhD
Scleroderma is a chronic autoimmune disease with no known cure. In this condition, B immune cells mistakenly produce antibodies that target the body’…
Douglas Brownfield, PhD
This project aims to test whether a new type of molecule can help the lungs heal themselves after injury. These molecules, called OPROTACs, are…
Paolo Provenzano, PhD
Fibrotic diseases, including those affecting the lungs, liver, kidneys, heart, and skin, negatively impact millions of people in the United States…
Andrew Khalil, PhD, Brenda Ogle, PhD, and Anna Kellner, PhD
Radiotherapy is a cornerstone of modern cancer treatment, using ionizing radiation to destroy tumor cells in over half of all patients. While…
David Deyle, MD
Neurofibromatosis type 1 (NF1) is a common genetic condition marked by features such as café-au-lait skin spots, freckling in the underarm and groin…
Bhairab Singh, PhD, John Bischof, PhD, and Brenda Ogle, PhD
3D-engineered heart tissue (3D-EHT) has emerged as a promising strategy for repairing the heart after a heart attack. Preclinical studies have…
Melanie Graham, MPH, PhD
This project focuses on a major translational bottleneck: the lack of robust preclinical models. Minnesota BRIDGE will create a state-of-the-art…
David Largaespada, PhD
Addressing the critical need for quality and safety standards in gene-edited therapies, this new consortium will bring together academic and industry…